BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program

Reuters01-12

Jan 11 (Reuters) - Regenxbio Inc RGNX.O:

REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAM
REGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHS
REGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026
REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026
REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026

Source text: ID:nPnbck1LKa

Further company coverage: RGNX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602504755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602504755","market":"nz","top_or_hot":-1,"title":"BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a> <span>RGNX.O</span>:</p><ul><li><p>REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAM</p></li><li><p>REGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHS</p></li><li><p>REGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026</p></li><li><p>REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026</p></li><li><p>REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026</p></li></ul><p>Source text: <span>ID:nPnbck1LKa</span></p><p>Further company coverage: <span>RGNX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a> <span>RGNX.O</span>:</p><ul><li><p>REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAM</p></li><li><p>REGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHS</p></li><li><p>REGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026</p></li><li><p>REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026</p></li><li><p>REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026</p></li></ul><p>Source text: <span>ID:nPnbck1LKa</span></p><p>Further company coverage: <span>RGNX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B2B36J28.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA1MGFYP:1","article_id":"2602504755","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602504755","pubTimestamp":1768161707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy ProgramJan 11 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO HIGHLIGHTS KEY","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","RGNX":"Regenxbio Inc","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4581":"高盛持仓","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4566":"资本集团","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","ABBV":"艾伯维公司","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4588":"碎股","BK4550":"红杉资本持仓","LU1732800096.USD":"摩根大通环球收益基金A (irc)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC"},"translate_title":"简介-Regenxbio强调了2026年的关键催化剂，并宣布了领先的杜氏基因治疗计划的积极长期功能结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"RGNX":0.9},"content_text":"BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy ProgramJan 11 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO HIGHLIGHTS KEY 2026 CATALYSTS AND ANNOUNCES POSITIVE LONG-TERM FUNCTIONAL OUTCOMES IN LEAD DUCHENNE GENE THERAPY PROGRAMREGENXBIO INC - NEW RGX-202 DATA SHOWS LONG-TERM EFFECT AT 18 MONTHSREGENXBIO INC - EXPECTING FDA PDUFA DECISION AND DATA READOUTS IN 2026REGENXBIO INC - TO RECEIVE $100 MILLION PAYMENT FROM ABBVIE IN 1H 2026REGENXBIO INC - EXPECTS PIVOTAL TRIAL DATA IN Q4 2026Source text: ID:nPnbck1LKaFurther company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602504755","isCrawlerRequest":true}